Bullish
Eli Lilly's Onswik insulin approval boosts stock to $1,184.38.
Eli Lilly's stock rose to $1,184.38 following the FDA's approval of Onswik, a once-weekly insulin for type 2 diabetes. This approval is expected to enhance the company's position in the diabetes treatment market.
Key points
- FDA approves Onswik, a once-weekly insulin for type 2 diabetes.
- Eli Lilly's stock closed at $1,184.38 on September 25, 2026.
- The Q2 revenue rose 48% to $22.97 billion.
Sources
AI-generated from public news sources. Not financial advice.
